Merel A A Opdam (M A A Opdam, Merel Opdam)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Systemic Lupus Erythematosus

Palliative Care

Rheumatoid Arthritis

Top Venues

Clinical rheumatology

Rheumatology (Oxford, England)

Rheumatology advances in practice

JMIR human factors

This page only lists publications with an associated author ORCID identifier.

Publications

Merel A A Opdam, N den Broeder, B J F van den Bemt, K Mulder, K M van de Wiel, H van Ballegooijen, R van Crevel, A A den Broeder
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical rheumatology 43 (6) (2024)
Merel A A Opdam, N den Broeder, B J F van den Bemt, K Mulder, K M van de Wiel, H van Ballegooijen, R van Crevel, A A den Broeder
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical rheumatology 43 (6) (2024)
Merel A A Opdam, N den Broeder, B J F van den Bemt, K Mulder, K M van de Wiel, H van Ballegooijen, R van Crevel, A A den Broeder
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical rheumatology (2024)
Merel A A Opdam, N den Broeder, B J F van den Bemt, K Mulder, K M van de Wiel, H van Ballegooijen, R van Crevel, A A den Broeder
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical rheumatology 43 (6) (2024)
Lara D Veeken, Merel A A Opdam, Lise M Verhoef, Calin Popa, Reinout van Crevel, Alfons A den Broeder
Infection incidence, timing, and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study. Rheumatology (Oxford, England) (2023)
Merel A A Opdam, Johanna E Vriezekolk, J Broen, Alfons A den Broeder, Lise M Verhoef
Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study. Rheumatology advances in practice 7 (1) (2023)
Merel A A Opdam, Laura M Campisi, J H de Leijer, David Ten Cate, Alfons A den Broeder
Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors. Rheumatology (Oxford, England) (2023)
Jeffrey van der Ven, Bartholomeus J F van den Bemt, Liset van Dijk, Merel A A Opdam, Lex L Haegens, Johanna E Vriezekolk, Lise M Verhoef
Preferences of Patients With Musculoskeletal Disorders Regarding the Timing and Channel of eHealth and Factors Influencing Its Use: Mixed Methods Study. JMIR human factors 10 (2023)
Merel A A Opdam, Johanna E Vriezekolk, J Broen, Alfons A den Broeder, Lise M Verhoef
Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study. Rheumatology advances in practice 7 (1) (2023)
Merel A A Opdam, J H de Leijer, Nathan den Broeder, Rogier M Thurlings, Wilfred van der Weele, Michael T Nurmohamed, Marc R Kok, Lenny van Bon, David F Ten Cate, Lise M Verhoef, Alfons A den Broeder
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B-cells. Rheumatology (Oxford, England) (2022)